Profile of BRCA testing in ovarian cancer patients in the United States and European Union.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16565-e16565
Author(s):  
Sabina Heinz ◽  
Pieter De Richter ◽  
Ayse Levent ◽  
Stella Moss ◽  
Jerzy Tyczynski
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
European Union ◽  
Cancer Patients ◽  
The United States ◽  
Brca Testing

Investigating reasons for discontinuation of first-line adjuvant chemotherapy among ovarian cancer patients in the midwestern United States.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e17523-e17523
Author(s):  
Kristin S. Weeks ◽  
Sherri L. Stewart ◽  
Michele West ◽  
Ryan Carnahan ◽  
Jacob Oleson ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
The United States ◽  
Comorbid Conditions ◽  
First Line ◽  
Midwestern United States ◽  
Platinum Based Chemotherapy ◽  
Line Chemotherapy

e17523 Background: Receipt of surgery and adjuvant chemotherapy greatly impact survival outcomes for ovarian cancer, the deadliest gynecologic malignancy with a high recurrence/progression rate. Most patients receive first-line, platinum-based chemotherapy. Platinum-based chemotherapy causes severe side effects, including nephrotoxicity and myelosuppression. Evidence for other chemotherapeutic agents is lacking and options are limited for women who cannot tolerate first-line chemotherapy. We aimed to determine the prevalence of premature first-line chemotherapy discontinuation and to detail reasons for discontinuation. Methods: We used the population-based cohort, Patterns of Ovarian Cancer Care and Survival in the Midwestern Region of the United States—a CDC Investigation, comprised of women diagnosed with histologically confirmed, stage IB-IV ovarian cancer in 2010-2012 in the Midwestern United States (i.e., Iowa, Kansas and Missouri) between the ages of 18 and 89 years. We limited the cohort to patients who received cancer-directed surgery and initiated adjuvant chemotherapy. Chemotherapy lines, completion, and reasons for discontinuation were abstracted from patient medical records by cancer registrars using standardized protocols. Results: Nineteen percent (N= 107/559) of ovarian cancer patients who initiated adjuvant chemotherapy did not complete first-line treatment. Reasons for chemotherapy discontinuation included toxicity or other kinds of intolerance (39%), poor quality of life or comorbid conditions (19%) or exhibited no response (17%) (Table). No significant differences were observed between gynecologic oncologists and non-gynecologic oncologist chemotherapy providers (p=0.109). Conclusions: One in 5 women who initiated did not complete first-line chemotherapy. Reasons were varied and suggested that lack of tolerance is not the only factor in discontinuation. Lack of response and the presence of comorbid conditions are considerations that can be taken into account during decision-making processes for treatment. More clinical research into additional chemotherapy options that may be useful in these patients is necessary.[Table: see text]

Introduction

2011 ◽  
Vol 21 (Supp 1) ◽  
pp. S1-S2 ◽  
Author(s):  
Andrés Poveda
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
European Union ◽  
Case Fatality Rate ◽  
Gynecological Cancer ◽  
Case Fatality ◽  
The United States ◽  
Fatality Rate ◽  
The European Union ◽  
Gynecological Malignancies

Ovarian cancer is the second most common gynecological cancer, representing 5% of all cancers in women. It has the highest case-fatality rate of all gynecological malignancies. In the European Union, there are approximately 48,000 new cases of ovarian cancer and 31,000 deaths per year. Similarly, in the United States, there are approximately 25,500 new cases per year, with 16,000 deaths associated.

Disparities in the survival trends in epithelial ovarian cancer patients in the United States

2018 ◽  
Vol 149 ◽  
pp. 142-143
Author(s):  
J.K. Chan ◽  
A.K. Mann ◽  
A.H. Freeman ◽  
C.I. Liao ◽  
L. Delic ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
The United States

Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1589-1589
Author(s):  
Jennifer Jorgensen ◽  
Kimberley Chiu ◽  
Kristin Gotimer ◽  
Eva Chalas ◽  
Dennis Yi-Shin Kuo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Counseling ◽  
Cancer Patients ◽  
Teaching Hospital ◽  
The United States ◽  
Brca Testing ◽  
Testing Model ◽  
Counseling And Testing ◽  
Testing Uptake ◽  
The Impact

1589 Background: BRCA testing has become an integral component of ovarian cancer management; however, low testing uptake remains an obstacle. This study evaluated the impact of an oncologist-led counseling and testing model on BRCA testing uptake. Methods: The ENGAGE study (NCT02406235) is a prospective study of an oncologist-led BRCA counseling and testing model in patients with epithelial ovarian, primary peritoneal and fallopian tube cancer (EOC). The United States lead accruing gynecologic oncology sites were Montefiore, an urban academic medical center; and Winthrop, a suburban teaching hospital. Oncologists were trained in BRCA counseling prior to site activation, and directly submitted patients’ samples for BRCA testing. Prior to the ENGAGE study, EOC patients were referred to genetics professionals for counseling and testing. We determined the number of BRCA tests performed, and simple descriptive statistics were used to summarize the data. Results: A combined total of 141 EOC patients underwent BRCA testing during the 20 consecutive months analyzed. In the 10 months pre-ENGAGE, 8 Montefiore patients had BRCA testing, all submitted through the genetics division. Nineteen Winthrop patients had BRCA testing, 16 from their oncologist’s office and 3 from an external genetics office. During the 10-month ENGAGE trial, 64 Montefiore patients and 50 Winthrop patients had BRCA testing. This represents a four-fold increase in BRCA testing uptake, with 114 patients tested during ENGAGE versus 27 patients tested pre-ENGAGE. Of these 114, 99 had BRCA counseling and testing through their oncologist’s office. Conclusions: Implementation of an oncologist-led genetic counseling and testing model was associated with increased BRCA testing among ovarian cancer patients in both the urban and suburban hospitals. Increased BRCA testing could be related to increased patient convenience and standardized training of the clinical team. These findings may guide other institutions as they implement streamlined genetic counseling and testing protocols.

Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States

2015 ◽  
Vol 136 (3) ◽  
pp. 491-497 ◽  
Author(s):  
Katherine C. Fuh ◽  
Jacob Y. Shin ◽  
Daniel S. Kapp ◽  
Rebecca A. Brooks ◽  
Stefanie Ueda ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
The United States ◽  
Survival Differences

scholarly journals Taxus Populations and Clippings Yields at Commercial Nurseries

1994 ◽  
Vol 4 (4) ◽  
pp. 372-377 ◽  
Author(s):  
Robert C. Hansen ◽  
Kenneth D. Cochran ◽  
Harold M. Keener ◽  
Edward M. Croom
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Natural Product ◽  
Cancer Patients ◽  
Dry Weight ◽  
The United States ◽  
Weight Basis ◽  
Breast Cancers ◽  
Renewable Source ◽  
State Area

A natural product known as taxol has been approved by the FDA for treatment of ovarian and breast cancers. In addition, preliminary clinical studies have shown encouraging results when using taxol to treat melanomas, lung, head, and neck cancers. Ornamental yews have been identified as a potential renewable source of taxol and related taxanes. Commercial nurseries were surveyed during Summer and Fall 1991 as a basis for estimating populations of Taxus cultivars currently growing in the United States. Clippings of selected cultivars were sampled from nursery fields in Ohio and Michigan to estimate expected clippings yields as a function of cultivar and cultivar age. More than 30 million Taxus plants were reported to be grown by the 19 major nurseries that responded to the survey. About 88% of all Taxus plants reported in the survey were grown in the three-state area of Ohio, Michigan, and Pennsylvania. Taxus × media `Densiformis', `Hicksii', and `Brownii' were found to be grown by nearly all nurseries in the survey; more than half grew T. × media `Wardii' and T. cuspidata `Capitata', while other well-known cultivars seem to have been specialties of one or two nurseries. Annual clippings yields on a dry-weight basis (db) ranged from ≈20 g/plant to 140 g/plant. Expected yields were found to be very dependent upon plant age and cultivar. Taxus × media `Hicksii' appeared to be the most ideal ornamental yew that could provide a renewable source of taxol because of immediate availability and potential for mechanical harvesting of upright clippings. An estimated 3000 to 4000 ovarian cancer patients could be treated annually with the taxol currently available for extraction from T. × media `Hicksii' clippings.

Sign in / Sign up

Export Citation Format

Share Document